Aspira Women's Health Inc. 8-K

What Happened

• Aspira Women's Health Inc. announced on its Form 8‑K (filed June 9, 2026) that it closed a private placement on June 5, 2026, issuing 3,300,000 shares of common stock and warrants. The gross proceeds to the company were approximately $1.485 million. The company said net proceeds will be used for working capital and general corporate purposes.

Key Details

• Purchase price: $0.45 per share (each share sold with an accompanying warrant).
• Warrants: Common Warrants to purchase up to 4,455,000 shares, exercisable immediately at $0.75 per share, with a three‑year term.
• Closing date and proceeds: Closing occurred June 5, 2026; gross proceeds ≈ $1.485 million (before offering expenses).
• Other terms: Purchasers are accredited/institutional investors; the purchase agreement includes customary terms (representations, conditions, termination rights) and an anti‑dilution provision. Purchasers received customary registration rights for the shares and shares underlying the warrants.

Why It Matters

• This financing provides immediate cash (about $1.5M) to fund Aspira’s near‑term operations and general corporate needs, which can help sustain ongoing activities without issuing debt.
• The warrants could lead to further equity dilution if exercised (up to 4,455,000 additional shares), and their exercise price ($0.75) and three‑year term create potential future share issuance and capital inflow.
• Investors should note the size of the raise relative to the company’s market capitalization and monitor any future filings about use of proceeds, additional financings, or warrant exercises for potential impact on share count and ownership.